Cabotegravir demonstrated efficacy as a long-acting PrEP, with no new HIV cases in the PILLAR trial over 12 months. The combination of cabotegravir and rilpivirine showed high viral suppression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback